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Background: Joint replacement surgery has been on the increase in recent decades and prosthesis
infection remains the most critical complication. Many aspects of the primary prevention and clinical
management of such prosthesis infections still need to be clarified.
Controversial issues: The aim of this GISIG (Gruppo Italiano di Studio sulle Infezioni Gravi) working group
– a panel of multidisciplinary experts – was to define recommendations for the following controversial
issues: (1) Is a conservative surgical approach for themanagement of prosthetic joint infections effective?
(2) Is the one-stage or the two-stage revision for the management of prosthetic joint infections more
effective? (3) What is the most effective treatment for the management of prosthetic joint infections due
to methicillin-resistant staphylococci? Results are presented and discussed in detail.
Methods: A systematic literature search using the MEDLINE database for the period 1988 to 2008 of
randomizedcontrolledtrials and/ornon-randomizedstudieswasperformed.Amatrixwascreatedtoextract
evidence from original studies using the CONSORT method to evaluate randomized clinical trials and the
Newcastle–Ottawa Quality Assessment Scale for case–control studies, longitudinal cohorts, and retrospec-
tivestudies.TheGRADEmethodforgradingqualityofevidenceandstrengthofrecommendationwasapplied.
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Prosthetic joint infections (PJI) result in substantial morbidity,
often with pain, immobility, prolonged hospital stay, and further
surgery, and thus additional costs.1,2 The incidence of PJI varies
depending on the joint involved; the rate of arthroplasties
becoming infected is as follows: 1.7% of primary and 3.2% of
non-primary hip arthroplasties; 2.5% of primary and 5.6% of non-
primary knee arthroplasties; and 1.3% of shoulder arthroplasties.3
However, the real overall risk per patient-life is unknown, since in
most case series only the first 2 years after implantation are
considered.4ses. Published by Elsevier Ltd. All rights reserved.
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conducted a matched case–control study to determine risk factors
for PJI. A multiple logistic regression model indicated that risk
factors for PJI were the development of a surgical site infection not
involving the prosthesis (odds ratio (OR) 35.9, 95% confidence
interval (CI) 8.3–154.6), a National Nosocomial Infections Surveil-
lance System (NNIS) surgical patient risk index score of 1 (OR 1.7,
95% CI 1.2–2.3) or 2 (OR 3.9, 95% CI 2.0–7.5), the presence of a
malignancy (OR 3.1, 95% CI 1.3–7.2) and a history of joint
arthroplasty (OR 2.0, 95% CI 1.4–3.0).5 Other risk factors have been
identified, such as rheumatoid arthritis, immunocompromised
states, diabetes mellitus, poor nutritional status, obesity, psoriasis,
long-term urinary catheterization, and extreme age.6 Whether or
not HIV infection and low CD4+ lymphocyte counts are risk factors
for surgical wound infections remains controversial.7,8
An internationally accepted classification for PJI has not yet
been established. The infections can be classified in accordance
with time of onset after surgery as: early, delayed, or late. Early
manifestation is defined as the appearance of the first signs and
symptoms of infection during the first 3 months after surgery.
However, some authors limit these surgical site infections to the
first 2–4 weeks. Delayed manifestation is defined as an infection
causing the first signs and symptoms between 3 months and 2
years after surgery. Finally, late manifestation is defined as the
appearance of the first signs and symptoms of infection >2 years
after surgery.2,9
Staphylococcus aureus and coagulase-negative staphylococci
account for approximately 50% of such infections, regardless of the
type of implant. Others are anaerobes, Gram-negative bacteria
such as Pseudomonas species or Escherichia coli, Propionibacterium
acnes and, especially in hematogenous infections, Streptococcus
spp.9 Polymicrobial PJIs account for 4–27% of all PJI infections.10
Unusual pathogens have also been reported.11,12 No microorgan-
isms are detected in about 10% of apparent infections.13 Establish-
ing a microbiological diagnosis is imperative because the type of
infecting organism often determines the therapeutic approach.2 In
addition, the rising prevalence of methicillin-resistant staphylo-
cocci further complicates matters.14 Successful treatment of these
infections usually requires surgical interventions and prolonged
antimicrobial therapy to achieve microbial sterilization and a
satisfactory functional result. Possible options for the operative
management of a PJI include debridement with retention of the
prosthesis, immediate one-stage exchange arthroplasty, and
resection arthroplasty, either as a definitive procedure or as the
first of a two-stage reconstructive procedure.2
The aim of this work was to define recommendations for some
controversial issues on the management of PJI, using an evidence-
based approach.
2. Methods
2.1. Controversial issues
As part of a large ‘evidence-based’ study on the management of
multidrug-resistant Gram-positive infections, eight national
experts were selected on the basis of their personal curricula
andwere asked to identify threemajor categories of bone and joint
infections and several questions to be addressed for each category.
Subsequently, during two workshop meetings held in Milan, Italy,
we restricted our work to three main controversial issues listed
below:
 Is a conservative surgical approach for the management of
prosthetic joint infections effective?
 Is the one-stage or the two-stage revision for the management of
prosthetic joint infections more effective? What is the most effective treatment for the management of
prosthetic joint infections due to methicillin-resistant staphylo-
cocci?
2.2. Literature search and study selection
A literature search using the MEDLINE database for the period
1988–2008 was performed. Studies were included if they were
written in English, involved human subjects, involved adults, and
involved PJI of the knee or hip. We included studies that showed
the following data for the three designed controversial issues:
systemic antibiotic therapy plus prosthesis retention and debride-
ment compared with systemic antibiotic therapy plus other
surgical approach OR one-stage surgical approach compared with
two-stage surgical approach OR systemic antibiotic therapy active
on methicillin-resistant staphylococci compared with another
systemic antibiotic therapy active on methicillin-resistant staph-
ylococci, respectively. We assessed the following outcomes:
revision of the surgical site, relapse of infection,mortality, duration
of hospitalization, cost-effectiveness, and quality of life.
Three specific search strategies were used. For the first issue,
the search terms used were: ((knee replacement arthroplasty OR
knee prosthesis OR hip replacement arthroplasty OR hip prosthe-
sis) AND (infection OR infections)) AND (salvage therapy OR
prosthesis retention OR debridement OR conservative treatment).
For the second issue, the search terms used were: ((knee
replacement arthroplasty OR knee prosthesis OR hip replacement
arthroplastyOR hip prosthesis) AND (infectionOR infections)) AND
(‘one stage’ OR ‘single stage’ OR ‘1 stage’) AND (‘two-stage’ OR ‘2
stage’ OR reoperation). Finally, for the third issue, the search terms
usedwere: ((prosthetic joint OR joint prosthesis OR periprosthetic)
AND (infection OR infections)) AND ((methicillin resistant AND
(Staphylococcus OR staphylococci)) OR (methicillin resistant
coagulase negative AND (Staphylococcus OR staphylococci)))
AND anti-bacterial agents. Titles and abstracts of potentially
relevant studies were checked: when studies met eligibility
criteria (or when information was insufficient to exclude them),
full text articles were obtained. Finally, if the search showed a lack
of clinical comparative trial, non-comparative studies (observa-
tional, retrospective, case report, and case series) were included.
These were sought using the same database and terms. Additional
references were identified from citations in published papers
included in the revision. These additional studies were included if
published in the last 10 years (1998–2008).
2.3. Classification and evaluation of selected evidence
We assessed methodological quality of randomized controlled
trials and non-randomized studies using the CONSORTmethod and
Newcastle–Ottawa Quality Assessment Scale, respectively. Details
of quality assessment and summaries of all included studies are
available from author SL. The original data from case studies were
considered homogeneous after using a predefined format both for
single case reports and series of reported cases. In the discussion
section, to assign the strength to the level of recommendation, a
methodology adapted from the GRADE Working Group was
applied. Details of the methodology are reported in this supple-
ment.15
3. Results
3.1. Is a conservative surgical approach for the management of
prosthetic joint infections effective?
Ten comparative non-randomized studies were included in the
analysis. Additional data were found in 21 non-comparative
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Figure 1. Studies included.
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the clinical validity of the algorithm published by Zimmerli et al.
based on the interval after implantation (early, delayed, late
manifestations are defined as the appearance of the first signs and
symptoms of infection during the first 3 months, between 3
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Figure 2. Algorithm for the surgical and antibiotic managmonths and 2 years, and at >2 years after surgery, respectively),
the type of infection (exogenous vs. hematogenous), the condition
of the implant, the soft tissue, and the patient co-morbidities
(Figure 2).2,4,16–19 According to these recommendations, debride-
ment with retention of the prosthesis is a reasonable option forement of prosthetic joint infection (adapted from2,4).
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infection, if the duration of clinical signs and symptoms is less than
3 weeks, the implant is stable, the soft tissue is in good condition,
and an agent with activity against biofilm-producing microorgan-
isms is available (e.g., rifampin).4 Overall, a conservative approach
was effective in 36 (69.2%) of 52 patients.
In the analysis of Betsch et al. on prosthetic hip- and knee-
associated infection, independent risk factors for treatment failure
were a high infection score (hazard ratio (HR) 1.24, 95% CI 1.10–
1.40; p < 0.001), choice of a surgical treatment strategy in
disagreement with published recommendations (HR 1.96, 95% CI
0.97–3.95; p = 0.05), and an inadequate antimicrobial regimen (HR
2.79, 95% CI 1.21–6.45, p = 0.01).16 In infection associated with hip
arthroplasty, Giulieri et al. showed that retention with debride-
ment had a success rate of 64% (7/11 patients) overall, and of 71% if
the indication was chosen according to the algorithm proposed by
Zimmerli.17 In infection associated with knee arthroplasty, Laffer
et al. observed that retention had an overall success rate of 95.2%
(20/21 patients), with a rate of 100% if the retention was treated
surgically with synovectomy (10 episodes) or 90.9% with
arthroscopic lavage.18 Finally, Ko¨sters et al. found a low efficacy
of conservative approach in the management of prosthetic knee-
associated infection (37.5%; 3/8 patients), but only four patients
were treated with the above-mentioned recommendations (suc-
cess rate of 75% – 3/4 patients) overall.19
Additional studies showed that retention of implants was
higher in early and acute hematogenous infections as opposed to
late infections.20–29 However, in some studies, the duration of
symptoms prior to administration of antibiotics and the timing of
infection did not appear to predict success or failure. Segreti et al.
reviewed 18 patients with PJIs who had been treated with a
conservative approach and prolonged antimicrobial suppression.
Of these, nine patients (50%) had an early onset infection and eight
(44%) experienced an acute inflammatory syndrome. Fifteen of the
18 patients (83.3%) appear to have had a favorable clinical outcome
and to have retained a functional prosthesis.30 In a prospective
study on long-term suppression of PJIs, Rao et al. confirmed a
favorable outcome in 86.2% (31/36) of patients after amean follow-
up of 5 years.31
Berbari et al. designed a retrospective study to estimate the
probability of treatment failure for patients with PJI and
rheumatoid arthritis treated with various surgical modalities.
The number of episodes treated with debridement and retention
was 46. Sinus tract and duration of symptoms < 30 days were
observed in 46% and 76%, respectively. The rate of survival free of
treatment failure at 5 years for the episodes treated with a
conservative approach was 32% (95% CI 21–49%). Compared with
joints treated with two-stage exchange, joints treated with
debridement and retention had a 5.9-fold increased risk of
treatment failure (95% CI 2.6–13.4-fold; p < 0.001).32 In another
retrospective study on 60 culture-negative PJIs, the same authors
showed that the 5-year estimate of survival free of treatment
failure was 71% (95% CI 44–100%) for patients treated with
debridement and retention. Although the difference was not
statistically significant, patients who underwent debridement and
retention had an increased risk of treatment failure by a factor of 5,
compared with those who underwent two-stage exchange (HR
4.80, 95% CI 0.88–27.3; p ( 0.07).13 Marculescu et al. evaluated the
outcome of PJIs treated with debridement and retention of
components. Variables associated with an increased risk of
treatment failure in multivariable analysis included the presence
of a sinus tract (HR 2.84, 95% CI 1.48–5.44; p = 0.002) and a
duration of symptoms prior to debridement of 8 days (HR 1.77,
95% CI 1.02–3.07; p = 0.04).33
Six studies have investigated the role of a rifampin-based
regimen on the management of PJIs.34–39 Four papers reported theoutcome of debridement and prosthesis retention with rifampin
and fluoroquinolone (ciprofloxacin or levofloxacin) combination.
The rate of successwas 65–100%. Overall, the efficacywas higher in
patients with a stable implant, shorter duration of symptoms,
earlier diagnosis, hip infections, andmethicillin susceptibility.34–39
Only, one study evaluated the combination of rifampin and fusidic
acid. The cumulative risk of treatment failure after 1 year was
11.76% (95% CI 3.08–39.40%).39
Recently, Soriano et al. investigated the role of linezolid for
orthopedic implant infections (n = 85) caused by methicillin-
resistant S. aureus (MRSA) and other multidrug-resistant Gram-
positive bacteria. For acute (n = 24) and chronic (n = 61) infections,
the respective success rates were 100% and 92.3% when the
implant was removed and 72.2% and 42.8% when it was not. The
cure rates of the conservative approach and linezolid/rifampin
combination in acute and chronic cases were 87.5% and 46.6%,
respectively.40 A few authors have reported that patients infected
by S. aureus have a more unfavorable clinical outcome than
patients infected with other bacteria .30 In 31 acute Gram-positive
infections after total knee arthroplasty treated with debridement
and component retention, only one (8%) of the 13 patients infected
with S. aureuswas successfully treated, compared with 10 (56%) of
18 patients with either Staphylococcus epidermidis or a streptococ-
cal species (p < 0.007).41 A good outcome in patients with
infections caused by streptococci was found in two series.42,43
Finally, two studies reported that arthroscopic surgical treatment
of PJIs is an appealing method, but that it should be used only in
selected circumstances, such as in medically unstable or antic-
oagulated patients.44,45
3.2. Is the one-stage or the two-stage revision for the management of
prosthetic joint infections more effective?
Four comparative non-randomized studieswere included in the
analysis. Additional data were found in 10 non-comparative series
(Figure 1). As for the first controversial issue, three studies
evaluated the clinical validity of the algorithm published by
Zimmerli et al. (Figure 2).2,4,16–18 According to these recommenda-
tions, if the duration of signs or symptoms of infection exceeds 3
weeks, retention of the implant should not be attempted. One-
stage revision is suitable for patients with non-compromising soft
tissue situations, in the absence of severe coexisting illnesses, and
in the absence of difficult-to-treat microorganisms (MRSA and
other multidrug-resistant bacteria). A two-stage revision is chosen
in patients with the above-mentioned microorganisms, as well as
in those with sinus tracts, swelling, or extended abscess formation
in depth.4
Success rates after one-stage exchange and after two-stage
exchange were 0% (0/4 episodes) and 65% (33/51 episodes) in the
study by Betsch et al., 94% (15/16 episodes) and 90% (28/31
episodes) in the study by Giulieri et al., and 100% (2/2 episodes)
and 85% (11/13 episodes) in the study by Laffer et al.16–18 Overall,
the choice of a surgical strategy in agreement with the algorithm
increased healing rates from 40% to 60% in the study by Betsch
et al., from62% to 88% in the study byGiulieri et al., and from86% to
92% in the study by Laffer et al.
In a small retrospective study by Pagnano et al. on the clinical
outcome after reinfection following hip arthroplasty reimplanta-
tion, only patients treated with two-stage exchange had a
favorable outcome.46 An additional four reports provided outcome
data on 103 direct exchange arthroplasties. Coagulase-negative
staphylococci were the most common isolates (n = 48). Polymi-
crobial PJIs were observed in nine cases. Antibiotic-impregnated
bone cement was used in 66 of these procedures (64%). Winkler
et al. performed a one-stage uncemented revision using cancellous
allograft bone impregnated with antibiotics in 37 patients. PJI was
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from 1.4 to 19.6 years.47–50
Six papers reported data on 246 episodes treated with two-
stage exchange. Success was achieved in 222 cases (90.2%) with a
follow-up ranging from 0.4 to 8.7 years.25,51–55 Of note, Hirakawa
et al. showed that reimplantation was successful in 80.0% of knees
with low-virulence organisms (coagulase-negative Staphylococ-
cus, Streptococcus), 71.4% with polymicrobial organisms, and
66.7% with high-virulence organisms (MRSA). Reimplantation was
successful in 82% of patients with osteoarthritis and in 54% of
patients with rheumatoid arthritis (p = 0.024).51
Finally,Mont et al. performed a comparative study to determine
whether aspiration of the affected joint and culture of the
specimen, performed before reimplantation and after discontinu-
ation of antibiotic therapy, would help to identify patients who
might have a recurrent infection. Group I consisted of 35 patients
treated with removal of the prosthetic components and irrigation
and debridement of the joint, followed by 6 weeks of antibiotic
therapy and reimplantation of the prosthesis. Group II was
composed of 34 patients treated with removal of the components
and irrigation and debridement of the joint, 6 weeks of antibiotic
therapy, and culture of further biological samples 4weeks after the
end of the antibiotic course. In the case of a culture-negative
sample, the patient was managed with a second-stage reimplan-
tation of a prosthesis. In the case of a culture-positive sample, the
protocol was applied again, with irrigation and debridement. Of
the 35 patients in group I, five (14%) had recurrence of infection. Of
the 34 patients in group II, three (9%) had a positive culture after
the antibiotic course. The protocol was repeated for all three
patients with a successful second revision. One other patient (3%)
in group II with a negative culture, had a recurrent infection and
was finally managed with arthrodesis of the knee.54
3.3. What is the most effective treatment for the management of
prosthetic joint infections due to methicillin-resistant staphylococci?
No comparative studies were found, and required data were
collected from 18 non-comparative series only (Figure 1).
Pavoni et al. used a conservative approach to treat 34 patients
with PJI. Identified pathogensweremethicillin-susceptible S. aureus
(MSSA; four infections), MRSA (eight infections), methicillin-
susceptible S. epidermidis (four infections), methicillin-resistant S.
epidermidis (five infections), Enterococcus faecalis (two infections),
methicillin-resistant S. epidermidis plus E. faecalis (one mixed
infection), and MRSA plus Pseudomonas aeruginosa (one mixed
infection).Most infectionswere initially treatedwith intravenous or
intramuscular teicoplanin  ciprofloxacin or rifampin. In patients
with MRSA and methicillin-resistant S. epidermidis infections, oral
minocycline 200 mg/day, either alone or in combinationwith rifampin
600 mg/day, was the usual subsequent therapy. In infections involving
methicillin-resistant staphylococci, a favorable outcome was reported
in 14 of 15 patients (93.3%). Among these, no relapse was observed in
seven patients (46.7%) during the follow-up; improvement with early
(6 months from antibiotic discontinuation) or late relapse was
observed in three (20%) and three (20%) patients, respectively; one
patient improved clinically, but he continued the antibiotic therapy.24
Only one study examined the effectiveness of co-trimoxazole
for the treatment of orthopedic implants infected with multidrug-
resistant Staphylococcus spp. All patients were treated orally with
high-dose co-trimoxazole (trimethoprim, 20 mg/kg of body
weight/day; sulfamethoxazole, 100 mg/kg/day). Patients with
prosthetic hip infections were treated for 6 months, with removal
of any unstable prosthesis after 5 months of treatment; patients
with prosthetic knee infections were treated for 9 months, with
removal of any unstable prosthesis after 6 months of treatment;
and patients with infected osteosynthetic devices were treated for6 months, with removal of the device after 3 months of treatment,
if indicated. Treatment success rates were 66.7% (26/39 patients)
after a follow-up of 24–75 months (average 38 months): the
success rates were 62.5% (5/8 patients) for patients with prosthetic
knee infections, 50% (6/12 patients) for patientswith prosthetic hip
infections, and 78.9% (15/19 patients) for patients with other
device infections. Seventeen of the 28 (60.7%) patients with a
conservative approach were cured. The remaining 11 patients
(36.6%) were treated with the removal of the prosthesis and nine
(81.8%) of them were completely cured; eight patients suspended
the treatment for adverse events and one patient was lost to
follow-up.56
In another study, the fusidic acid/rifampin oral combination
was effective in 10 of 11 (90.9%) patients with infections involving
MRSA. In one patient the persistence of the PJI required the
removal of the prosthesis 6months after the initial debridement.39
A similar favorable outcome was observed in the study of
Drancourt et al., which compared fusidic acid/rifampin with
ofloxacin/rifampin combination. Overall, treatment was successful
for 11 of 20 patients (55%) treated with rifampin and fusidic acid
and for 11 of the 22 patients (50%) treated with rifampin and
ofloxacin.57
Seven studies investigated the role of linezolid in the treatment
of PJIs.40,58–63 A retrospective study of therapy with linezolid for
patients with PJIs reported that treatment was successful in the
80% of cases (16/20 patients). Pathogens isolated were: MRSA, 14
strains; methicillin-resistant coagulase-negative staphylococci,
five strains; and Enterococcus spp, one strain. Eleven patients
(55%) had an early onset infection, with an acute onset reported in
nine cases (45%). The mean duration of linezolid administration
was 7.2 weeks. Several antibiotics were administered before
linezolid, including vancomycin and the combination rifampin/
ciprofloxacin.62
Rao et al. prospectively monitored 51 consecutive adults on
linezolid therapy for 53 Gram-positive orthopedic infections,
chronic osteomyelitis (n = 25) and PJIs (n = 23). Identified patho-
gens were S. aureus (n = 27) and coagulase-negative staphylococci
(n = 19); 38 of them were methicillin-resistant. After clinical
remission, 17 patients with PJI required long-term suppression.
The most common adverse events were thrombocytopenia (n = 5)
and anemia (n = 5); treatment discontinuation was indicated in
three patients.53
In six original articles the use of daptomycin for PJIs was
reported on a cumulative number of 22 cases.64–69 In four cases a
favorable clinical outcome was reported using a 6-mg/kg/day
dosage in association with rifampin or other antibiotics.64,66,67,69
Rao et al. reported clinical failure in five patients with a
conservative approach treated with 4 mg/kg/day.65
Finally, one study analyzed the role of quinupristin–dalfopristin
in the treatment of MRSA infections including bone and joint
infections. Cure or improvement was observed in 31 of 40 (77.5%)
cases.70
3.4. From the evidence to the recommendations
Infections associated with prosthetic joint implantations occur
only in a small proportion of joint recipients, but they represent a
severe event. The use of perioperative antimicrobial prophylaxis
and a laminar airflow surgical environment has reduced the risk of
intraoperative infection to less than 1% after hip and shoulder
replacement and to less than 2% after knee replacement.2 Since
several controversial issues still remain in the management of
patients with PJI, a panel of Italian multidisciplinary experts have
analyzed all published studies in the last 20 years in order to
provide an answer to three basic questions and to propose a
standard algorithm for diagnosis and cure.
Recommendations
We suggest the use of the conservative approach whenever
possible, with the proper selection of eligible patients. This
approach should be used only if the following specific conditions
are met: a stable implant; a pathogen with susceptibility to
antimicrobial agents active against surface-adhering microor-
ganisms (e.g., rifampin); absence of a sinus tract or an abscess;
and a duration of symptoms of infection of less than 3weeks (B).
We suggest that after a 2-week course of intravenous
antibiotic therapy, that this should be replaced with an oral
rifampin-based regimen (A). Moreover, we suggest the use of
oral antibiotics with high bioavailability when possible (D).
Patients with hip prostheses should be treated for 3months and
those with knee prostheses for 6 months (A). After the
treatment period, a new white blood cell (WBC) scintigraphy
should be performed together with laboratory tests, to verify
the absence of infection (D).
We suggest that after 3–6months of antimicrobial treatment,
the oral therapy should be stopped if the patient has no signs and
symptomsand if C-reactive protein (CRP) is negative for at least 6
weeks, and/or a WBC scintigraphy is also negative (D).
We recommend the use of rifampin-based regimens as the
cornerstone of therapy for the PJIs, except in the circumstances
in which antimicrobial resistance prevents its use (A).
We recommend that the first option rifampin-based regimen
for susceptible organisms is the combination with a fluoro-
quinolone (A).
In the case of multidrug-resistant bacteria, we suggest that
the use of other agents active against surface-adhering, slow-
growing, and biofilm-producing microorganisms, such as
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prosthetic joint infections effective?
Here the duration of symptoms has been considered to be a
reliable predicting factor of treatment outcome. In the analysis by
Marculescu et al., duration of symptoms 8 days was a risk factor
for treatment failure33 (GRADE score 3). Tattevin et al. showed that
of the 34 patients initially treated with debridement alone, only 13
(38.2%) required no further surgery. These 13 patients, had
significantly shorter intervals between onset of symptoms and
surgical treatment than the 21 patients treated with a second
intervention (4.8 vs. 54.2 days; p < 0.0001)26 (GRADE score 3).
In 19 cases of streptococcal PJIs with a duration of symptoms
before debridement of 4 days (range 1–10 days), Meehan et al.
showed that treatment failure occurred in two cases (10.5%) during
a median follow-up period of 3.9 years (range 0.3–21.7 years)43
(GRADE score 3). In a prospective study, Chiu and Chen followed 40
PJIs treated with surgical debridement and parenteral antibiotics
with retention of their existing prostheses. Using the classification
of Tsukayama et al., 10, 20, and 10 patients had types I (acute
postoperative), II (late chronic), and III (acute hematogenous)
infections, respectively. Successful implant salvage was achieved
in 12 of the 40 patients (30%). However, a favorable outcome
depended on the type of infection: patientswith type I infection (7/
10) and patients with type III infection (5/10) retained their
prostheses more often than patients with type II infection (0/20)20
(GRADE score 3). Favorable results were observed by authors who
treated patients with clinical signs and symptoms of less than 3
weeks16–19 (GRADE score 3 for each paper).
A loose prosthesis has been assumed to be a contraindication to
debridement and retention of the prosthesis, and several studies
have excluded such patients16–19,27,33,43 (GRADE score 3 for each
paper). The presence of a sinus tract or an abscess is an additional
predictor of treatment failure16–19,33 (GRADE score 3 for each
paper). Finally, the antimicrobial agent should have bactericidal
activity against surface-adhering, slow-growing and biofilm-
producing microorganisms2 (GRADE score 2).
Rifampin has excellent efficacy to eliminate stationary phase
staphylococci invitroandinclinical trials71 (GRADEscore3). There is
only one randomized placebo-controlled study for the treatment of
patients with orthopedic device-related infection34 (GRADE score
4). The patients were treated with debridement without removal
combined with either ciprofloxacin plus placebo or ciprofloxacin
plus rifampin. There was a complete cure rate of staphylococcal
orthopedic implant-related infections in all patients who tolerated
long-term therapy with ciprofloxacin plus rifampin.34 Additional
studies have shown the clinical efficacy of the rifampin/fluoroquin-
olone combination35–38 (GRADE score 3 for each paper). However,
fluoroquinolone resistance is now at high levels in nosocomial
strains of staphylococci, thereby limiting the usefulness of rifampin
andfluoroquinolone combinations in this setting72 (GRADE score 2).
These organisms usually remain susceptible to fusidic acid, but this
drug is not available in Italy39 (GRADE score 3). In this scenario, the
newer drugs appear to be attractive for this indication.
In the setting of catheter-related bloodstream infections, Raad
et al. investigated the efficacies of thenewer antibiotics daptomycin,
linezolid, and tigecycline, in comparisonwith vancomycin, minocy-
cline, and rifampin, against MRSA embedded in biofilm. Minocy-
cline, daptomycin, and tigecycline were more efficacious in
inhibiting MRSA in biofilm than linezolid, vancomycin, and the
negative control (p < 0.001) after the first day of exposure to these
antibiotics. Minocycline was the most active, followed by dapto-
mycin and then tigecycline, whereas vancomycin and linezolid
lacked bactericidal activity, similar to the negative control. After 3
days of 4-h daily exposures, daptomycin was the fastest in
eradicating MRSA from biofilm, followed by minocycline andtigecycline, which were faster than linezolid, rifampin, and
vancomycin (p < 0.001). When rifampin was used alone, it was
less effective in eradicating MRSA from biofilm, due to the
emergence of rifampin-resistant MRSA. However, when rifampin
was used in combination with other antibiotics, the combination
was effective in eliminating MRSA colonization from biofilm more
rapidly than any single antibiotics alone73 (GRADE score 1).
In another model, Baldoni et al. showed that linezolid used in
combination with rifampin was more effective than linezolid used
as monotherapy, reducing the planktonic bacteria (p < 0.05)74
(GRADE score 1). However, a negative drug interaction between
linezolid and rifampin that resulted in decreased serum linezolid
levels was identified in an in vivo study75 (GRADE score 1).
Finally, John et al. compared the activity of daptomycin (alone
and with rifampin) with other antimicrobial regimens against
MRSA in the guinea pig foreign-body infection model and
concluded that daptomycin plus rifampin is a promising treatment
option for implant-associated MRSA infections76 (GRADE score 1).
In conclusion, we have shown that debridement and retention
of prosthesis has a higher likelihood of treatment success in the
following situations: PJIs involving a stable implant; infection by a
pathogen with susceptibility to antimicrobial agents active against
surface-adhering microorganisms (e.g., rifampin); the absence of a
sinus tract or an abscess; if the duration of symptoms of infection is
less than 3 weeks.3.6. Is the one-stage or the two-stage revision for the management of
prosthetic joint infections more effective?
The literature analysis failed to report a better clinical
outcome of one surgical treatment compared to the other for
glycopeptides, minocycline, co-trimoxazole, and in selected
case linezolid and daptomycin, can be considered (D).
Recommendations
We recommend the two-stage exchange procedure as the
more effective treatment option. This is the first option in
patients with compromised soft tissue and difficult-to-treat
microorganisms. The interval between surgeries should be a
minimum of 6 weeks (C).
In the case of suspicion of persistent infection before
reimplantation (elevated CRP and/or positive WBC scintigra-
phy), a joint aspiration should also be performed and a new
debridement should be planned (D).
In the case of high likelihood of sterilization (CRP persis-
tently in the normal range and/or negative WBC scintigraphy),
the surgery approach can be planned. However, during surgery
it is advisable to perform an intraoperative frozen section to rule
out active infection. In the case of histological evidence of
infection, >5 neutrophils per at least five high-power fields at a
magnification of  400 (B) and a second debridement with
replacement of the spacer must be done (D).
We suggest that antibiotics should not routinely be
administered after the second stage surgical procedure.
Nevertheless, if the histopathological examination and
culture performed during the second stage surgical procedure
are positive, a further surgical debridement should be
performed with the same management as for early infections
(D).
We recommend following the diagnostic and therapeutic
algorithm developed by our working group (D).
We suggest the use of a one-stage revision only in selected
circumstances with careful selection of patients as follows:
no need for a bone graft; an aggressive debridement of all
infected tissues; satisfactory condition of the soft tissue;
absence of difficult-to-treat microorganisms; and an organ-
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to identify clinical reports on the use of direct exchange
arthroplasty or surgical debridement with prosthesis retention
to treat infected knee arthroplasties. This search revealed 35
studies, including 37 knees that underwent direct exchange
arthroplasty. Infection was controlled in 33 of 37 infected total
knee arthroplasties that were treated by direct exchange
arthroplasty (89.2%). Antibiotic-impregnated bone cement was
used in 32 (86.5%) of these procedures. Determinant factors
associated with the successful direct exchange arthroplasty were
infection by Gram-positive organisms, the absence of sinus
formation, the aggressive debridement of all infected tissues, the
use of antibiotic-impregnated bone cement for fixation of the
new prosthesis, and the long-term use of antibiotic therapy77
(GRADE score 2).
Jackson et al. performed a literature review to determine
parameters related to a successful direct exchange in the
treatment of infected total hip replacements. Twelve reports
provided outcome data on 1299 infected hip replacements. Of
these, 1077 (83%) were thought to be free of infection at the last
follow-up. The average duration of follow-up was 4.8 years, but
the range was broad (0.1–17.1 years). Antibiotic-impregnated
bone cement was used in 1282 of the cases (99%). Determinant
factors associated with a successful direct exchange included
the absence of wound complications after the initial total hip
replacement, good general health of the patient, methicillin-
sensitive staphylococci and Streptococcus spp, and an organism
sensitive to the antibiotic mixed into the bone cement78 (GRADE
score 2). This surgical procedure appears to offer several
advantages such as lower morbidity (single surgery), shorter
hospital stay, lower costs, and better functional outcome.
Nevertheless, it should only be used if the following specific
conditions are found: no need for a bone graft; lack of fistula; no
difficult-to-treat bacteria; extensive debridement; and use of
antibiotic-impregnated cement79 (GRADE score 2). Unfortunate-
ly, only a limited number of cases meet the above-mentioned
criteria making a favorable outcome with direct exchange highly
probable.
Conversely, the two-stage procedure has the highest success
rate usually exceeding 90%4,80 (GRADE score 2 for each paper).
The annual relapse rate of this strategy is between 0.6% and
8.3%25,26,81,82 (GRADE score 3 for each paper). The prerequisites
for this surgical method include adequate bone stock and
minimal medical co-morbidities to allow for multiple surgical
procedures2 (GRADE score 2). The ideal interval between the
two surgeries is not well established, but it frequently results in
considerable economic hardship and morbidity. The interval
usually accepted is a minimum of 6 weeks, during which
antibiotic therapy is prescribed79 (GRADE score 2). In infections
with difficult-to-treat microorganisms, an interval of 6–8 weeks
between removal of the first prosthesis and placement of the
second, is preferable2 (GRADE score 2). In addition, several
others factors must be included in the evaluation of the timing
of reimplantation. CRP is elevated after surgery but normalizes
in 2–4 weeks83 (GRADE score 3); but persistent elevation of CRP
is highly suggestive of infection. The combination of a normal
erythrocyte sedimentation rate and CRP level is reliable for
predicting the absence of infection84 (GRADE score 3). A cell
count and culture of the aspirate should be obtained during joint
aspiration.
Mont et al. determined whether aspiration of the affected joint
and culture of the specimen, performed before the reimplantation
and after the discontinuation of the antibiotic therapy, would help
to identify patients who might have a recurrence. The authors
concluded that cultures of biological samples performed after the
discontinuation of the antibiotic treatment and before thereimplantation, help to identify patients at high risk of recurrence
of infection54 (GRADE score 3). The use of antibiotics before
aspiration, however, can cause false-negative results. Thus, a 4- to
6-week antibiotic wash-out before aspiration is recommended85,86
(GRADE score 2 for each paper).
However, it is our opinion that the antibiotic therapy should not
be stopped before reimplantation. In this setting, frozen sections
for diagnosing persistent infection at the time of reimplantation
may be useful86 (GRADE score 2). Histopathological examination of
periprosthetic frozen tissue to detect more than five neutrophils
per at least five high-power fields at a magnification of  400 has a
very high sensitivity and specificity87–89 (GRADE scores 3, 3, and 2,
respectively).
Finally, it is important to mention that the diagnostic
approach may strongly influence the clinical therapeutic
decision. To this regard the possibility of including a diagnostic
scintigraphy with radiolabeled autologous WBC has been shown
to significantly improve the specificity of diagnosis for infection
and determine the time for reimplantation of prosthesis90
(GRADE score 2).
In conclusion, a diagnostic and therapeutic algorithm was
developed by our working group as shown in Figure 3.3.7. What is the most effective treatment for the management of
prosthetic joint infections due to methicillin-resistant staphylococci?
For the third controversial issue, some limitations need to be
discussed. Firstly, our revision lacks comparative studies to
ism that is sensitive to the antibiotic mixed into the bone
cement (C).
[(Figure_3)TD$FIG]
Figure 3. Diagnostic and therapeutic algorithm developed by GISIG group (adapted from2,4,107).
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management of PJI due to methicillin-resistant staphylococci.
Secondly, the use of antibiotics for the treatment of MRSA PJI is
characterized by different biases. Several drugs are approved with
non-specific generic indication. For example, glycopeptides are
only prescribed for the treatment of serious, life-threatening
infections by susceptible Gram-positive isolates that are unre-
sponsive to other antibiotics. In contrast, some drugs are
commonly prescribed for not-approved indications: off-label
prescription. For example, the new antibiotics (e.g., linezolid,
daptomycin) should be used to treat complicated skin and skin
structure infections caused by susceptible strains. These agents are
not currently approved for the management of PJI. Thirdly, our
revision lacks ad hoc studies on the use of vancomycin in the
management of PJI. This is paradoxical, since this antibioticwas the
only therapeutic option for MRSA PJIs in the last decade, at least in
the USA.
Indeed, in the available studies on the use of new antibiotics
for the treatment of patients with PJIs, the majority of patients
received new drugs only when vancomycin and/or teicoplanin
were ineffective. In addition, only one case series on teicoplanin
was included in the analysis24 (GRADE score 3). Moreover,
according to several author suggestions, teicoplanin can be given
once daily or three times a week, which makes it a first choice for
outpatient treatments (OPAT)91,92 (GRADE score 2 for each
paper). For the treatment of bone or prosthetic infections withthis agent, a Cmin >20 mg/l should be obtained
93–96 (GRADE
scores 2, 2, 3, 2, respectively). However, these agents have some
limitations. There is a growing body of evidence indicating that
glycopeptide minimum inhibitory concentration (MIC) has an
impact on patient outcome97 (GRADE score 2). For example, in a
retrospective cohort study, Lodise et al. showed that patients
with vancomycin MICs of 1.5 mg/l had a 2.4-fold increase in
failure compared to patients with MICs of 1.0 mg/l (36.4% and
15.4%, respectively; p = 0.049). In the Poisson regression analy-
sis, a vancomycin MIC of 1.5 mg/l was independently associat-
ed with failure (adjusted risk ratio (ARR) 2.6, 95% CI 1.3–5.4;
p = 0.01)98 (GRADE score 3). Soriano et al. observed that
mortality associated with MRSA bacteremia was significantly
higher when the empirical antibiotic was inappropriate and
when vancomycin was empirically used for the treatment of
infection with strains with a high (>1 mg/l) vancomycin MIC99
(GRADE score 3).
Recently, a multidisciplinary consensus suggested that in
severe bacterial infections caused by S. aureus, a total trough
serum vancomycin concentration of 15–20 mg/l should be
achieved. These recommendations are based on the potential
to improve penetration, increase the probability of optimal target
serum vancomycin concentrations, and improve clinical out-
comes. Trough serum vancomycin concentrations in that range
should achieve an area under the curve (AUC)/MIC ratio of 400
in most patients if the MIC is 1 mg/l. In order to achieve rapid
Table 1
Treatment options for prosthetic joint infections due to MRSA
Parenteral agents Oral agentsa,b
First option Alternative option First option Alternative option
Standard option for initial treatment and MIC
<1 mg/l or unknown MIC
Glycopeptide Daptomycin
or linezolid
Minocycline
or co-trimoxazole
Linezolid
Slow response, relapse or breakthrough MRSA
bacteremia and/or MIC >1.0 mg/l
Daptomycin
or linezolid
Daptomycin
or linezolid
Linezolid Co-trimoxazole
or minocycline
Known MIC >1.0 mg/l of glycopeptide, and previous,
optimally conducted glycopeptide therapy
Daptomycin
or linezolid
Daptomycin
or linezolid
Linezolid Co-trimoxazole
or minocycline
MRSA, methicillin-resistant Staphylococcus aureus; MIC, minimum inhibitory concentration.
Note: all drugs with or without rifampin: afor sequential antibiotic therapy; bfusidic acid not available in Italy.
Recommendations
There is no evidence that any single agent or combination of
agents is superior to the other (D).
We suggest that glycopeptides are themainstay of treatment
for MRSA PJIs. The first-line use of glycopeptides with other
adjunctive agents such as rifampin is endorsed. Vancomycin
and teicoplanin should achieve trough levels >15 mg/l and
>20 mg/l, respectively. An increase in the nephrotoxicity is a
likely risk with the use of higher dosages (C).
In the setting where a high (>1 mg/l) vancomycin MIC is
reported, we suggest the use of the new antimicrobial options
alternative to glycopeptides (D).
In the case of treatment with linezolid or daptomycin for the
treatment of MRSA PJI, we recommend dosages of 600 mg twice
daily and at least 6 mg/kg once daily, respectively (A and C,
respectively).
There are no data demonstrating the need/possibility of
different durations of treatment with new antimicrobial agents
(D).
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loading dose of 25–30 mg/kg can be considered100 (GRADE score
2). However, there are increasing questions regarding the
toxicity of such regimens101 (GRADE score 3). A targeted AUC/
MIC of 400 is not achievable with conventional dosing methods
if the vancomycin MIC is 2 mg/l in a patient with normal renal
function. Therefore, alternative therapies should be considered.
Thus, the isolates causing serious infections and failing to
respond to glycopeptide therapy should certainly have their MIC
checked.
In addition, glycopeptides showed a worse activity than new
drugs against stationary-phase and non-dividing S. aureus cells
that are common in persistent infections such as PJI. Moreover, the
new drugs showed a good tissue penetration. In patients
undergoing total hip replacement, Lovering et al. showed that
linezolid rapidly penetrated into bone, fat, and muscle at the
operation site, to achieve levels in excess of its MIC for susceptible
organisms (4 mg/l). With the soft tissue samples, fat concentra-
tions of linezolid at the time of operationwere similar to itsMIC for
susceptible pathogens, whereas muscle concentrations exceeded
the MIC by a factor of three or four, suggesting good penetration
into the tissues surrounding the bone. This is supported by the
concentrations of linezolid found in drainage from these tissues,
which exceeded simultaneous blood levels for up to 12 h after
dosing and were above the MIC for susceptible pathogens
throughout the dosing interval102 (GRADE score 1). In addition,
Rana et al. demonstrated that at steady-state, linezolid penetrates
osteoarticular tissues well. Synovial fluid, synovium, muscle, and
bone penetration was 91.9%, 82.1%, 83.5%, and 40.1%, respective-
ly103 (GRADE score 1).
There have been no clinical trials for daptomycin, although in
vitro data suggest that it penetrates bone well. Recently, Rouse
et al. measured the mechanical strength of daptomycin- and
vancomycin-loaded polymethylmethacrylate (PMMA), and
assayed in vivo release of daptomycin and vancomycin from
daptomycin- and vancomycin-loaded PMMA, respectively. The
authors showed that treatment with parenteral daptomycin or
vancomycin for 21 days results in significantly reduced numbers of
bacteria in bone surrounding the infection site in a rat model of
experimental osteomyelitis104 (GRADE score 1). Previously, the
same authors have shown that daptomycin is released from PMMA
in a continuous flow chamber at a rate similar to that of
vancomycin105 (GRADE score 1). Finally, the ideal dose of
daptomycin has not well established. On this point, Lamp et al.
observed that the clinical success rate for patients affected by
osteomyelitis and orthopedic device infections treated with an
initial daptomycin dose4 mg/kgwas significantly higher than for
patients treated with an initial dose 4 mg/kg (88% vs. 65%;
p = 0.013)106 (GRADE score 2).
In conclusion, the new antimicrobial options offer potential
alternatives to glycopeptides (Table 1).Acknowledgement
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